PharmaShots | Incisive News in 3 Shots

Subscribe Now

ITM

ITM’s ITM-11 Receives the FTD by the US FDA for the Treatment of Neuroendocrine Tumors

ITM’s ITM-11 Receives the FTD by the US FDA for the Treatment of Neuroendocrine Tumors

October 27, 2022

ITM Entered into a Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 to Treat Solid Tumors

ITM Entered into a Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 to Treat Solid Tumors

July 21, 2022

ITM Signs an Exclusive License Agreement with Grand Pharma to Develop & Commercialize Oncological Radiopharmaceutical Therapies in the Greater China

ITM Signs an Exclusive License Agreement with Grand Pharma to Develop & Commercialize Oncological Radiopharmaceutical Therapies in...

December 28, 2021

ITM Entered into a Research Collaboration with Navigo to Develop FAP-targeting Radionuclide Therapy for Solid Tumors

ITM Entered into a Research Collaboration with Navigo to Develop FAP-targeting Radionuclide Therapy for Solid Tumors

December 2, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us